Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study.

Clicks: 309
ID: 106529
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #31 of 309 articles by views in Frontiers in pharmacology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 309 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA). To evaluate the 2-year retention rate of adalimumab in PsA patients. Potential baseline parameters influencing persistence on treatment were also evaluated. PsA patients from 16 Italian Rheumatology Units treated with adalimumab as first- or second-line biological therapy were retrospectively evaluated. Adalimumab retention rate was evaluated at 12 and 24 months. Logistic regression was used to evaluate the association between predictor variables and adalimumab retention rate. From 424 patients (53.5% male, aged 48.3 ± 12.8 years) who started treatment with adalimumab, 367 (86.6%) maintained treatment for 12 months and 313 (73.8%) for 2 years. At 24-months, Disease Activity in PsA (DAPSA) remission (defined as ≤4) and Low Disease Activity (LDA) (≤14) were achieved in 22.8% and 44.4% of patients, respectively. Adalimumab treatment significantly decreased the number of tender (7.0 ± 5.7 at baseline vs. 2.3 ± 3.5 at 24 months, p < 0.001) and swollen joints (2.7 ± 2.8 at baseline vs. 0.4 ± 0.9 at 24 months, p < 0.001), DAPSA (25.5 ± 10.9 at baseline vs. 11.0 ± 8.4 at 24 months, p < 0.001), PASI (5.3 ± 5.7 at baseline vs. 2.7 ± 2.8 at 24 months, p < 0.001) and CRP (3.8 ± 6.3 at baseline vs. 1.2 ± 1.7 at 24 months, p < 0.001). Among a range of laboratory and clinical variables, only female gender was associated with improved adalimumab persistence at 24 months (OR: 1.98, 95% CI: 1.2-3.2, p = 0.005). Independent of a range of predictor variables, adalimumab was shown to be effective, while maintaining a high retention rate after 2 years in PsA patients.
Reference Key
dangelo2019effectivenessfrontiers Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors D'Angelo, Salvatore;Cantini, Fabrizio;Ramonda, Roberta;Cantarini, Luca;Carletto, Antonio;Chimenti, Maria Sole;Delle Sedie, Andrea;Foti, Rosario;Gerli, Roberto;Lomater, Claudia;Lubrano, Ennio;Marchesoni, Antonio;Zabotti, Alen;Salvarani, Carlo;Scrivo, Rossana;Scarpa, Raffaele;Tramontano, Giuseppina;Nannini, Carlotta;Lorenzin, Mariagrazia;Fabbroni, Marta;Martinis, Federica;Perricone, Roberto;Carli, Linda;Visalli, Elisa;Rovera, Guido;Perrotta, Fabio Massimo;Quartuccio, Luca;Altobelli, Alessio;Costa, Luisa;Niccoli, Laura;Ortolan, Augusta;Caso, Francesco;
Journal Frontiers in pharmacology
Year 2019
DOI
10.3389/fphar.2019.01497
URL
https://www.frontiersin.org/article/10.3389/fphar.2019.01497/full
Keywords
psoriatic arthritis adalimumab real-life biological drugs retention rate

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.